224 related articles for article (PubMed ID: 26910839)
1. MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells.
Xu M; Bian S; Li J; He J; Chen H; Ge L; Jiao Z; Zhang Y; Peng W; Du F; Mo Y; Gong A
Oncotarget; 2016 Mar; 7(12):14476-85. PubMed ID: 26910839
[TBL] [Abstract][Full Text] [Related]
2. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
3. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
Nguyen CT; Gonzales FA; Jones PA
Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
[TBL] [Abstract][Full Text] [Related]
4. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes.
Yaqinuddin A; Abbas F; Naqvi SZ; Bashir MU; Qazi R; Qureshi SA
Biosci Rep; 2008 Dec; 28(6):319-26. PubMed ID: 18666890
[TBL] [Abstract][Full Text] [Related]
5. Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I; Wischnewski F; Pantel K; Schwarzenbach H
BMC Cancer; 2010 Jun; 10():297. PubMed ID: 20565761
[TBL] [Abstract][Full Text] [Related]
6. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing.
Hamada T; Goto M; Tsutsumida H; Nomoto M; Higashi M; Sugai T; Nakamura S; Yonezawa S
Cancer Lett; 2005 Sep; 227(2):175-84. PubMed ID: 16112420
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer.
Okami J; Simeone DM; Logsdon CD
Cancer Res; 2004 Aug; 64(15):5338-46. PubMed ID: 15289340
[TBL] [Abstract][Full Text] [Related]
9. MeCP2 epigenetically regulates alpha-smooth muscle actin in human lung fibroblasts.
Xiang Z; Zhou Q; Hu M; Sanders YY
J Cell Biochem; 2020 Jul; 121(7):3616-3625. PubMed ID: 32115750
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells.
Law AY; Lai KP; Ip CK; Wong AS; Wagner GF; Wong CK
Exp Cell Res; 2008 May; 314(8):1823-30. PubMed ID: 18394600
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer.
Kim TW; Lee SJ; Oh BM; Lee H; Uhm TG; Min JK; Park YJ; Yoon SR; Kim BY; Kim JW; Choe YK; Lee HG
Oncotarget; 2016 Jan; 7(4):4195-209. PubMed ID: 26675260
[TBL] [Abstract][Full Text] [Related]
12. Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.
Deng J; Guo J; Guo X; Hou Y; Xie X; Sun C; Zhang R; Yu X; Liang H
Oncotarget; 2016 Jul; 7(28):43461-43474. PubMed ID: 27223257
[TBL] [Abstract][Full Text] [Related]
13. MeCP2 regulated glycogenes contribute to proliferation and apoptosis of gastric cancer cells.
Qin Y; Zhao L; Wang X; Tong D; Hoover C; Wu F; Liu Y; Wang L; Liu L; Ni L; Song T; Huang C
Glycobiology; 2017 Apr; 27(4):306-317. PubMed ID: 28100567
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
15. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes.
Yasui DH; Peddada S; Bieda MC; Vallero RO; Hogart A; Nagarajan RP; Thatcher KN; Farnham PJ; Lasalle JM
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19416-21. PubMed ID: 18042715
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
17. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.
Sohn BH; Park IY; Lee JJ; Yang SJ; Jang YJ; Park KC; Kim DJ; Lee DC; Sohn HA; Kim TW; Yoo HS; Choi JY; Bae YS; Yeom YI
Gastroenterology; 2010 May; 138(5):1898-908. PubMed ID: 20038433
[TBL] [Abstract][Full Text] [Related]
18. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
[TBL] [Abstract][Full Text] [Related]
19. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
